Swedish researchers have captured the first atomic snapshots of human SMUG1, an enzyme that works like a cellular repair crew inside our DNA, and the discovery opens new possibilities for cancer drug design. Until now, scientists had never seen the detailed three-dimensional structure of this crucial protein, leaving a significant gap in our understanding of how cells protect themselves from genetic damage.
DNA faces relentless assault—from the normal churn of cellular processes, from environmental hazards, and sometimes from cancer treatments themselves. When damage goes unrepaired, it locks into permanent mutations that can corrupt future cell generations. One of the body's frontline defenders is SMUG1, an enzyme that patrols DNA strands looking for uracil and other corrupted bases, then surgically removes them before they cause lasting harm. Uracil is a nucleotide base that belongs in RNA but wreaks havoc when it slips into DNA.
Led by professor Pål Stenmark at Stockholm University, the research team has now revealed SMUG1 in multiple states: standing alone, bound to uracil molecules, attached to 5-fluorouracil (a cancer drug), and clamped onto double-stranded DNA. "These structures give us the first detailed view of how human SMUG1 engages damaged DNA and carries out the first steps of repair," Stenmark explained. The findings, published in Nature Communications, represent a watershed moment for DNA repair biology.
What makes this work particularly noteworthy is the method itself. The team employed a rare combined approach—both neutron and X-ray crystallography—to resolve the atomic structure. This dual technique reveals something X-rays alone typically cannot: the precise positions of hydrogen atoms and the intricate hydrogen-bonding networks within the enzyme's active site, the molecular heart where damage recognition and removal actually happens. "This provides rare insight into proton positions and hydrogen-bonding networks in the enzyme active site, details that are often difficult to resolve with X-ray crystallography alone," Stenmark noted.
The connection to cancer biology amplifies the significance. The molecule 5-fluorouracil is a cytostatic agent—a drug that stops cancer cells from dividing—and is widely used in cancer treatment. Once incorporated into DNA, SMUG1 springs into action to remove it. Because SMUG1 activity bridges DNA repair and cancer biology, these new atomic blueprints provide a foundation for designing drugs that could precisely target the enzyme, potentially refining how we treat cancer or protect healthy cells during therapy.
The research emerged from collaboration among Uppsala University, Karolinska Institutet, Institut Laue-Langevin (ILL), the European Spallation Source (ESS), and Stockholm University. Stenmark highlighted the timing's significance: "This finding is especially timely for Sweden, as the European Spallation Source (ESS), the world's most powerful neutron source, is currently being built in Sweden. This will dramatically expand opportunities for studies of this kind." As ESS comes online, it promises to unlock similar atomic-level insights into other cellular machinery, accelerating the pace of biomedical discovery.
For now, researchers hold a detailed picture of SMUG1's dance with damaged DNA—knowledge that will fuel the next generation of therapeutic development and deepen our grasp of how cells wage their silent war against genetic corruption.